DaVita (NYSE:DVA) Updates FY24 Earnings Guidance

DaVita (NYSE:DVA) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $9.25-$10.05 for the period, compared to the consensus EPS estimate of $9.90. DaVita also updated its FY 2024 guidance to 9.250-10.050 EPS.

DaVita Stock Up 1.5 %

DVA traded up $2.09 during trading on Friday, hitting $141.90. 226,554 shares of the company’s stock traded hands, compared to its average volume of 816,103. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 0.82 and a beta of 0.87. The company’s 50 day simple moving average is $157.96 and its two-hundred day simple moving average is $145.97. DaVita has a 12-month low of $76.64 and a 12-month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the business earned $2.85 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Analysts predict that DaVita will post 9.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the subject of several research reports. Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $161.80.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.